Online citations, reference lists, and bibliographies.
← Back to Search

MRI-based Radiogenomics Analysis For Predicting Genetic Alterations In Oncogenic Signalling Pathways In Invasive Breast Carcinoma.

P. Lin, W. Liu, X. Li, D. Wan, H. Qin, Q. Li, G. Chen, Y. He, H. Yang
Published 2020 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
AIM To investigate the effect of radiomics in the assessment of alterations in canonical cancer pathways in breast cancer. MATERIALS AND METHODS Eighty-eight biopsy-proven breast cancer cases were included in the present study. Radiomics features were extracted from T1-weighted sagittal dynamic contrast-enhanced magnetic resonance imaging (MRI) images. Radiomics signatures were developed to predict genetic alterations in the cell cycle, Myc, PI3K, RTK/RAS, and p53 signalling pathways by using hypothesis testing combined with least absolute shrinkage and selection operator (LASSO) regression analysis. The predictive powers of the models were examined by the area under the curve (AUC) of the receiver operating characteristic curve. RESULTS A total of 5,234 radiomics features were obtained from MRI images based on the tumour region of interest. Hypothesis tests screened 250, 229, 156, 785, and 319 radiomics features that were differentially displayed between cell cycle, Myc, PI3K, RTK/RAS, and p53 alterations and no alteration status. According to the LASSO algorithm, 11, 12, 12, 15, and 13 features were identified for the construction of the radiomics signatures to predict cell cycle, Myc, PI3K, RTK/RAS, and p53 alterations, with AUC values of 0.933, 0.926, 0.956, 0.940, and 0.886, respectively. The cell cycle radiomics score correlated closely with the RTK/RAS and p53 radiomics scores. These signatures were also dysregulated in patients with different oestrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 statuses. CONCLUSION MRI-based radiogenomics analysis exhibits excellent performance in predicting genetic pathways alterations, thus providing a novel approach for non-invasively obtaining genetic-level molecular characteristics of tumours.
This paper references
10.1002/jmri.25119
Breast cancer molecular subtype classifier that incorporates MRI features
E. Sutton (2016)
10.1158/0008-5472.CAN-12-4717
From integrative genomics to therapeutic targets.
R. Natrajan (2013)
10.1038/npjbcancer.2016.12
Quantitative MRI radiomics in the prediction of molecular classifications of breast cancer subtypes in the TCGA/TCIA data set
H. Li (2016)
10.1016/j.neuroimage.2006.01.015
User-guided 3D active contour segmentation of anatomical structures: Significantly improved efficiency and reliability
P. Yushkevich (2006)
10.1016/j.cell.2018.03.035
Oncogenic Signaling Pathways in The Cancer Genome Atlas
F. Sánchez-Vega (2018)
10.1038/nature12634
Mutational landscape and significance across 12 major cancer types
C. Kandoth (2013)
10.1126/science.1235122
Cancer Genome Landscapes
B. Vogelstein (2013)
10.1016/j.ctrv.2016.03.004
New insights on PI3K/AKT pathway alterations and clinical outcomes in breast cancer.
S. Yang (2016)
10.1158/0008-5472.CAN-13-2625
Loss of NF1 in cutaneous melanoma is associated with RAS activation and MEK dependence.
Moriah H Nissan (2014)
10.1038/s41586-019-1450-6
Loss of p53 triggers Wnt-dependent systemic inflammation to drive breast cancer metastasis
M. Wellenstein (2019)
10.1038/nrclinonc.2017.141
Radiomics: the bridge between medical imaging and personalized medicine
P. Lambin (2017)
10.1007/s10278-013-9622-7
The Cancer Imaging Archive (TCIA): Maintaining and Operating a Public Information Repository
K. Clark (2013)
10.1016/j.cell.2011.02.013
Hallmarks of Cancer: The Next Generation
D. Hanahan (2011)
10.1117/1.JMI.2.4.041007
Prediction of clinical phenotypes in invasive breast carcinomas from the integration of radiomics and genomics data
Wentian Guo (2015)
10.1001/jama.2018.19323
Breast Cancer Treatment: A Review
Adrienne G Waks (2019)
10.1158/1078-0432.CCR-17-3783
Radiomics Signature on Magnetic Resonance Imaging: Association with Disease-Free Survival in Patients with Invasive Breast Cancer
Hyunjin Park (2018)
10.1016/j.ccell.2018.07.009
Notch Signaling in the Tumor Microenvironment.
O. Meurette (2018)
10.1016/j.mri.2019.08.026
Evaluation of TP53/PIK3CA mutations using texture and morphology analysis on breast MRI.
W. K. Moon (2019)
10.1186/s40644-019-0197-5
CT-based peritumoral radiomics signatures to predict early recurrence in hepatocellular carcinoma after curative tumor resection or ablation
Q. Shan (2019)
10.1186/s41747-017-0025-2
Breast MRI radiomics: comparison of computer- and human-extracted imaging phenotypes
E. Sutton (2017)
10.1146/annurev-med-062913-051343
The PI3K/AKT Pathway as a Target for Cancer Treatment.
I. Mayer (2016)
10.1016/j.ebiom.2018.10.034
P53, GHRH, inflammation and cancer
N. Barabutis (2018)
10.1200/JCO.2016.69.0032
Cell-Cycle Therapeutics Come of Age.
Matthew D. Ingham (2017)
10.1038/nrc.2017.109
Targeting mutant p53 for efficient cancer therapy
V. J. Bykov (2018)
10.1007/s12094-019-02109-8
Multiparametric MRI-based radiomics analysis for prediction of breast cancers insensitive to neoadjuvant chemotherapy
Qianqian Xiong (2019)
10.3389/fcell.2017.00010
Strategies to Inhibit Myc and Their Clinical Applicability
Jonathan R Whitfield (2017)
10.1016/j.ejca.2011.11.036
Radiomics: extracting more information from medical images using advanced feature analysis.
P. Lambin (2012)
10.1001/jama.2019.3927
Treatment of Nonmetastatic Breast Cancer.
K. Ruddy (2019)
10.1158/1078-0432.CCR-15-1125
RAS/MAPK Activation Is Associated with Reduced Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Therapeutic Cooperation Between MEK and PD-1/PD-L1 Immune Checkpoint Inhibitors
S. Loi (2015)
10.1056/NEJMoa1813904
Alpelisib for PIK3CA‐Mutated, Hormone Receptor–Positive Advanced Breast Cancer
F. André (2019)
10.1016/j.cell.2013.03.002
Lessons from the Cancer Genome
L. Garraway (2013)
10.1038/srep17787
Deciphering Genomic Underpinnings of Quantitative MRI-based Radiomic Phenotypes of Invasive Breast Carcinoma
Y. Zhu (2015)
10.1001/jamanetworkopen.2019.2561
Association of Peritumoral Radiomics With Tumor Biology and Pathologic Response to Preoperative Targeted Therapy for HER2 (ERBB2)–Positive Breast Cancer
Nathaniel Braman (2019)
10.1093/bioinformatics/btx364
UpSetR: an R package for the visualization of intersecting sets and their properties
J. Conway (2017)
10.1016/j.celrep.2015.03.007
Opposing activities of Notch and Wnt signaling regulate intestinal stem cells and gut homeostasis.
H. Tian (2015)
10.3322/caac.21552
Artificial intelligence in cancer imaging: Clinical challenges and applications
W. Bi (2019)
10.1186/s41747-019-0117-2
Breast cancer Ki-67 expression prediction by digital breast tomosynthesis radiomics features
A. Tagliafico (2019)
10.3322/caac.21492
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
F. Bray (2018)
10.1038/nature07385
Comprehensive genomic characterization defines human glioblastoma genes and core pathways
Roger E. McLendon (2008)
10.1038/nrc.2016.76
The interplay between cell signalling and the mevalonate pathway in cancer
P. J. Mullen (2016)
10.1172/JCI95873
Pharmacological targeting of MYC-regulated IRE1/XBP1 pathway suppresses MYC-driven breast cancer
N. Zhao (2018)
10.1016/j.ccell.2017.06.010
Conditional Selection of Genomic Alterations Dictates Cancer Evolution and Oncogenic Dependencies.
M. Mina (2017)
10.1053/J.SEMNUCLMED.2019.06.005
Radiomics Analysis for Clinical Decision Support in Nuclear Medicine.
A. Ibrahim (2019)
10.1158/0008-5472.CAN-16-2479
High-Throughput Genomic Profiling of Adult Solid Tumors Reveals Novel Insights into Cancer Pathogenesis.
R. Hartmaier (2017)
10.1148/radiol.14132641
Radiogenomic analysis of breast cancer: luminal B molecular subtype is associated with enhancement dynamics at MR imaging.
M. Mazurowski (2014)
10.1148/radiol.2018172171
Precision Medicine and Radiogenomics in Breast Cancer: New Approaches toward Diagnosis and Treatment.
K. Pinker (2018)
10.1038/s41467-018-03867-9
Characterization of PIK3CA and PIK3R1 somatic mutations in Chinese breast cancer patients
L. Chen (2018)
10.1002/cncr.29791
Using computer‐extracted image phenotypes from tumors on breast magnetic resonance imaging to predict breast cancer pathologic stage
E. Burnside (2016)
10.1007/s11307-019-01423-5
Contrast-Enhanced Mammography and Radiomics Analysis for Noninvasive Breast Cancer Characterization: Initial Results
M. A. Marino (2019)
10.1016/j.jmir.2019.07.010
Personalized Breast Cancer Treatments Using Artificial Intelligence in Radiomics and Pathomics.
W. Tran (2019)



Semantic Scholar Logo Some data provided by SemanticScholar